Incannex Healthcare Achieves Interim Milestone in Phase 2 Psilocybin Clinical Trial
Australian pharmaceutical company, Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), has achieved its interim milestone of 29 patients completing primary endpoint assessments in a Phase 2 trial evaluating psilocybin-assisted psychotherapy for anxiety.
Incannex is developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs. Psilocybin-assisted psychotherapy has shown promise in the treatment of a number of mental health conditions.
- The 10-week trial is designed to assess the safety and efficacy of Incannex’s unique psilocybin program in an active placebo-controlled study.
- Quality of life and other aspects of mental and physical health will be assessed, along with safety and efficacy.
- An independent Data Safety Monitoring Board has commenced analysis of the interim study data.
Incannex is positioned to be one of the first companies in the world to develop a proprietary psychedelic therapy.